Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this research is to identify genetic factors that may affect the efficacy and safety of medical marijuana, regardless of condition. The pharmacogenomics test detects DNA variants, which may affect the way drugs work and are metabolized in the body and/or detect potential side effects.

Detailed Description
-----------------
This observational, population-based study will examine genetic differences between ultra-rapid, intermediate and poor metabolizers of various formulations of Columbia Care's medical cannabis products in order to identify genetic factors that may affect the efficacy and safety of medical marijuana, regardless of condition. The goal of the research is to establish relationships between cannabis consumers, cannabinoids, and consumer outcomes. The study is expected to enroll 150 subjects across three cohorts, high daily dose users (poor metabolizers) that take more than 50 mg of cannabinoids daily (n=50), low daily dose users (ultra-rapid metabolizers) that take less than 10 mg of cannabinoids daily (n=50), and a control group (intermediate metabolizers) that represents the median daily dose user taking between 11-21 mg of cannabinoids daily (n=50). Columbia Care Inc. has identified trends amongst its medical cannabis users suggesting that there are some patients who are high daily dose users and others who are low daily dose users, with both groups assumed to have similar satisfaction with the products. The complexity of the endocannabinoid system combined with individual genetic predisposition and gene-environment interactions likely result in the variation in response seen with cannabinoid treatment.

Official Title
-----------------
An Observational, Population-Based Study of Pharmacogenetic Variation to Identify Genetic Factors That May Affect the Efficacy and Safety of Medical Marijuana

Conditions
-----------------
New York Medical Marijuana Program Qualifying Conditions

Intervention / Treatment
-----------------
* Other: DNA Genotek Oragene 600


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and Females age 18 and older Currently obtaining medical marijuana products from Columbia Care LLC Willing to participate and consent to a DNA analysis Purchased product from Columbia Care for three consecutive encounters spanning a 6-month period Exclusion Criteria: Unwillingness to participate and consent to a DNA analysis Unwillingness to answer a survey/questionnaire on patient satisfaction as related to product efficacy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High daily dose users<br>Total Cannabinoid Daily Dose greater than 50 mg | Other: DNA Genotek Oragene 600<br>* Saliva-based DNA sample collection kit<br>|
| Control<br>Users that represent the median dose between high daily dose users and low daily dose users taking between 11-21 mg | Other: DNA Genotek Oragene 600<br>* Saliva-based DNA sample collection kit<br>|
| Low daily dose users<br>Total Cannabinoid Daily Dose less than 10 mg | Other: DNA Genotek Oragene 600<br>* Saliva-based DNA sample collection kit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of genetic factors | Saliva-based DNA sample will be tested for known genes (e.g., the cytochrome P-450 superfamily) | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction with therapy and adverse effects: survey | Survey tool will examine patient satisfaction with current dose as a covariate and evaluate adverse outcomes (e.g., mental health indications, reported unintended effects) based on varying doses and mode of exposure of cannabis within our analyses. | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Medical cannabis, Medical marijuana